ProPharma Group Executive and Leadership Team

Brian Tuttle, the Chief Financial Officer at ProPharma Group, manages the fiscal health and long-term financial strategy of the organization. Overseeing capital allocation and budgetary planning, the Chief Financial Officer ensures the company maintains the resources necessary to deliver high-quality regulatory and compliance solutions. This leadership role involves analyzing market trends to guide investment in new service lines and geographic expansion. By streamlining financial reporting processes, Brian Tuttle directly impacts the transparency and accountability of the firm. Tuttle coordinates with executive leadership to align fiscal objectives with the overarching goal of supporting medical industry clients. Through disciplined financial management, the Chief Financial Officer secures the stability required for sustained growth and innovation. This commitment to fiscal excellence allows the organization to provide consistent, high-value consulting services while navigating the complex economic requirements of the global medical and pharmaceutical regulatory sectors.

Daniel Ryan, the President, Clinical Research Solutions at ProPharma Group, leads the strategic execution of clinical trial management and research operations. Overseeing the delivery of end-to-end clinical services, the President, Clinical Research Solutions ensures compliance with global regulatory requirements throughout the drug development lifecycle. This leadership role involves coordinating cross-functional teams to accelerate research timelines while maintaining the highest standards of data integrity. By optimizing clinical trial processes, Daniel Ryan directly impacts the speed and efficiency with which medical innovations reach the market. Ryan collaborates with pharmaceutical partners to design robust research strategies that address specific therapeutic needs. Through the management of complex clinical programs, the President, Clinical Research Solutions drives the organization's mission to improve patient outcomes. This operational focus on clinical excellence enables the firm to provide critical support to medical organizations navigating the rigorous demands of modern clinical research and development.

Matthew Weinberg, the President, Regulatory Sciences at ProPharma Group, directs the strategic advisory services related to global regulatory submissions and compliance. Overseeing the navigation of complex health authority requirements, the President, Regulatory Sciences ensures that client products meet all necessary safety and efficacy standards. This leadership role involves managing interactions with regulatory bodies to facilitate smooth approval processes for medical innovations. By providing expert guidance on regulatory strategy, Matthew Weinberg directly impacts the success of client product launches in international markets. Weinberg coordinates with technical teams to ensure that all documentation and submissions adhere to evolving industry regulations. Through the oversight of regulatory science operations, the President, Regulatory Sciences supports the company's commitment to patient safety and industry compliance. This strategic leadership ensures that the organization remains a trusted partner for medical companies seeking to bring life-saving treatments to patients across the globe.

Jason DeGoes, the President at ProPharma Group, oversees the overall operational strategy and execution of the company's diverse service portfolio. Directing the integration of various business units, the President ensures that the organization delivers cohesive regulatory and compliance solutions to the medical industry. This leadership role involves setting the corporate vision and driving initiatives that enhance market presence and service quality. By aligning departmental goals with the broader mission, Jason DeGoes directly impacts the firm's ability to meet the complex needs of global clients. DeGoes manages the executive team to foster a culture of innovation and operational excellence. Through the coordination of cross-functional efforts, the President supports the company's growth and expansion into new therapeutic areas. This comprehensive oversight ensures that the organization maintains its position as a leader in providing essential regulatory support, ultimately contributing to the advancement of medical science and patient care.

James Kolbet, the President Life Science Consulting at ProPharma Group, leads the strategic consulting division focused on optimizing business processes for life science organizations. Overseeing the delivery of specialized advisory services, the President Life Science Consulting ensures that clients receive actionable insights to improve operational efficiency and compliance. This leadership role involves identifying market opportunities and developing tailored solutions that address the unique challenges of the medical industry. By driving the growth of the consulting practice, James Kolbet directly impacts the firm's ability to provide high-value strategic support. Kolbet collaborates with industry leaders to refine service offerings and expand the reach of the consulting division. Through the management of expert teams, the President Life Science Consulting supports the organization's mission to empower medical companies. This focus on strategic consulting excellence enables the firm to assist clients in navigating the complexities of the modern life science landscape.

Laura Hopper, the President, Pharmacovigilance at ProPharma Group, directs the global safety and risk management operations for medical products. Overseeing the monitoring and reporting of adverse events, the President, Pharmacovigilance ensures that client products maintain the highest safety standards throughout their lifecycle. This leadership role involves managing complex safety databases and coordinating with health authorities to address potential risks. By implementing proactive safety strategies, Laura Hopper directly impacts the protection of patient health and the maintenance of regulatory compliance. Hopper leads teams of safety experts to provide comprehensive pharmacovigilance support to pharmaceutical and medical device companies. Through the oversight of safety operations, the President, Pharmacovigilance supports the organization's commitment to rigorous medical oversight. This focus on safety and risk management ensures that the firm remains a critical partner for medical organizations dedicated to delivering safe and effective treatments to patients worldwide.

Kirk Wroblewski, the Chief Information Officer at ProPharma Group, directs the global digital infrastructure and data security protocols essential for regulatory compliance. Overseeing the integration of advanced technology platforms, the Chief Information Officer ensures seamless data management across all medical consulting operations. This leadership role involves architecting scalable cloud solutions that support secure information exchange for clients worldwide. By optimizing internal systems, Kirk Wroblewski directly impacts the efficiency of regulatory reporting and compliance monitoring. Wroblewski maintains rigorous standards for cybersecurity, protecting sensitive client data while driving digital transformation initiatives. Through the implementation of robust IT governance, the Chief Information Officer supports the broader mission of providing reliable, data-driven insights to the medical industry. This strategic focus on technological advancement enables the organization to maintain a competitive edge in the rapidly evolving landscape of global health compliance and regulatory consulting services.

Rachel Bias, the Chief Human Resources Officer at ProPharma Group, directs talent acquisition, organizational development, and employee engagement strategies. Overseeing the cultivation of a high-performance culture, the Chief Human Resources Officer ensures the firm attracts and retains top-tier experts in regulatory and compliance fields. This leadership role involves designing comprehensive training programs that keep staff at the forefront of medical industry standards. By fostering an inclusive and collaborative work environment, Rachel Bias directly impacts the productivity and morale of the global workforce. Bias aligns human capital initiatives with the strategic goals of the organization, ensuring that teams possess the necessary skills to address complex client challenges. Through effective workforce planning, the Chief Human Resources Officer supports the company's ability to scale operations across diverse international markets. This focus on human capital development remains central to maintaining the high level of expertise required for delivering superior regulatory consulting services.